Vol. 150, No. 11 — June 1, 2016

Registration
SOR/2016-107 May 20, 2016

CONTROLLED DRUGS AND SUBSTANCES ACT

Order Amending Schedules I and III to the Controlled Drugs and Substances Act (AH-7921, MT-45, W-18 and Lefetamine)

P.C. 2016-373 May 20, 2016

His Excellency the Governor General in Council, on the recommendation of the Minister of Health, pursuant to section 60 of the Controlled Drugs and Substances Act (see footnote a), deeming that it is necessary in the public interest, makes the annexed Order Amending Schedules I and III to the Controlled Drugs and Substances Act (AH-7921, MT-45, W-18 and Lefetamine).

Order Amending Schedules I and III to the Controlled Drugs and Substances Act (AH-7921, MT-45, W-18 and Lefetamine)

Amendments

1 Schedule I to the Controlled Drugs and Substances Act (see footnote 1) is amended by adding the following after item 22:

• 23 AH-7921 (1-(3,4-dichlorobenzamidomethyl)cyclohexyldimethylamine), its salts, isomers and salts of isomers
• 24 MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine), its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues, including
  • (1) Diphenidine (DEP) (1-(1,2-diphenylethyl)piperidine)
  • (2) Methoxphenidine (2-MeO-Diphenidine, MXP) (1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine)
  • (3) Ephenidine (NEDPA, EPE) (N-ethyl-1,2-diphenylethylamine)
  • (4) Isophenidine (NPDPA) (N-isopropyl-1,2-diphenylethylamine)
  • but not including
  • (5) Lefetamine ((-)-N,N-dimethyl-α-phenylbenzeneethanamine), its salts, derivatives and isomers and salts of derivatives and isomers
• 25 W-18 (4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]benzenesulfonamide), its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues

2 Item 29 of Schedule III to the Act is replaced by the following:

• 29 Lefetamine ((-)-N,N-dimethyl-α-phenylbenzeneethanamine), its salts, derivatives and isomers and salts of derivatives and isomers

Coming into Force

3 This Order comes into force on the 180th day after the day on which it is published in the Canada Gazette, Part II.

N.B. The Regulatory Impact Analysis Statement for this Order appears following SOR/2016-106, Regulations Amending the Food and Drug Regulations (Parts G and J — Lefetamine, AH-7921, MT-45 and W-18).

• Footnote a
  S.C. 1996, c. 19
• Footnote 1
  S.C. 1996, c. 19